LAS VEGAS, Jan. 10, 2022
The Cerebral Palsy emerging therapies such as Xeomin (Incobotulinum toxin A) which is expected to launch in a couple of quarters along with some late launches such as Myobloc (RimabotulinumtoxinB), cumulatively may generate more than USD 500 Million sales in major markets. These emerging treatments will complement the uptake of botulinum toxins which has had very good uptake so far and is expected to see a rise in demand in future too
LAS VEGAS, Jan. 10, 2022 /PRNewswire/ -- DelveInsight's "Cerebral Palsy Market" report provides a thorough comprehension of the Cerebral Palsy historical and forecasted epidemiology and the Cerebral Palsy market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Cerebral Palsy market report also proffers an analysis of the current Cerebral Palsy treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the necessary takeaways from the Cerebral Palsy Market Research Report
For further information on Market Impact by Therapies, visit: Cerebral Palsy Drugs Market Analysis
Cerebral Palsy is a group of disorders that affect movement and muscle tone or posture.
DelveInsight estimates that the total Cerebral Palsy diagnosed cases in the 7MM were around 1.8 million in 2020. Also, the total Cerebral Palsy prevalent cases of cerebral palsy in the United States were approximately 1 million cases in the same year.
The Cerebral Palsy Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into:
Get a complete epidemiological segmentation breakdown @ Cerebral Palsy Epidemiological Analysis
Cerebral Palsy Treatment programs encompass physical and behavioural therapy, pharmacologic and surgical treatments, mechanical aids, and management of associated medical conditions. In physical, occupational, speech, and behavioural therapies, the goals include enhancing patient and caregiver interactions while providing family support.
Currently, there is no cure for Cerebral Palsy. But pharmacological therapies can help pediatric patients with a lot of muscle pain and stiffness. They can take medicine by mouth or put it under the skin through a pump (the baclofen pump). Surgery can help fix dislocated hips and scoliosis, standard in pediatric patients with cerebral palsy, and leg braces can also help with walking.
Anticholinergic medications treat uncontrolled movements such as tremors, spasticity, and drooling. Anticonvulsants, which reduce excessive brain stimulation to prevent seizure activity. Antidepressants are often prescribed to those with cerebral palsy to help treat depression, anxiety, and seizures. Muscle relaxants are often the first line of treatment for spasticity in many cases, as the medications are non-invasive and fairly common. Anti-inflammatory medications decrease pain, which can be a significant part of hypoxic-ischemic encephalopathy-related cerebral palsy.
Major Cerebral Palsy therapies currently approved in the 7MM include Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA), among others. At present, some Cerebral Palsy companies have initiated clinical trials that investigate new treatment options. Key players such as Merz Pharmaceuticals (Xeomin), Teva Pharmaceuticals (Austedo), Supernus Pharmaceuticals (Myobloc), Rohto Pharmaceutical (UDI-001), and several others are investigating their candidates for Cerebral Palsy management in the 7MM.
Cerebral Palsy Market to increase due to the Stem cell therapy, which is a novel treatment for cerebral palsy compared with symptomatic standard care that has shown a significant positive effect on gross motor function. Also, increasingly compelling evidence that cerebral palsy can have a genetic component, studies are testing interventions such as deep brain stimulation (DBS) and personalized medicine for the treatment of Cerebral Palsy patients. However, the growth of the Cerebral Palsy Market will be hampered due to the limited availability of animal models for functional studies. Also, the issues of concern for children with cerebral palsy are wide-ranging, chronic, difficult to quantify, resistant to change, and more reflective of disability than illness. These parameters lead to frustration for the clinician who evaluates the status of a child with cerebral palsy. And there is a high unmet need for the current therapies for the treatment of Cerebral Palsy.
Scope of the Cerebral Palsy Market Insight Report
Request for a Webex demo of the report @ Cerebral Palsy Therapeutics Market
Table of Contents
Cerebral Palsy Key Insights
Cerebral Palsy Report Introduction
Cerebral Palsy Market Overview at a Glance
Executive Summary of Cerebral Palsy
Cerebral Palsy Disease Background and Overview
Cerebral Palsy Epidemiology and Patient Population
Country Wise-Epidemiology of Cerebral Palsy
The United States
The United Kingdom
Organizations contributing towards Cerebral Palsy
Cerebral Palsy Case Reports
Cerebral Palsy Patient Journey
Cerebral Palsy Marketed Therapies
Cerebral Palsy Emerging Therapies
Cerebral Palsy 7MM Market Analysis
The United States Cerebral Palsy Market Size
EU-5 Cerebral Palsy Market Size
Germany Market Size
France Market Size
Italy Market Size
Spain Market Size
The United Kingdom Market Size
Japan Cerebral Palsy Market Size
Cerebral Palsy Market Drivers
Cerebral Palsy Market Barriers
Cerebral Palsy SWOT Analysis
Cerebral Palsy Unmet Needs
Cerebral Palsy KOL Views
Browse full report with detailed TOC with charts, figures, tables @ Cerebral Palsy Diagnostics Market Report
View Other Reports
DelveInsight's Spastic Cerebral Palsy - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Cerebral Palsy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Cerebral Palsy.
DelveInsight's Spastic Cerebral Palsy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Spastic Cerebral Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Spastic Cerebral Palsy Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Spastic Cerebral Palsy market.
Browse Blog Posts
The key players operating in the segment of Migraine Neuromodulation Devices comprise Theranica Bio-Electronics LTD, electroCore, Inc., Cirrus Healthcare Products, Cefaly Technology, eNeura Inc., Prolivio, Neuros Medical, Neurolief Ltd., tVNS Technologies GmbH, Medtronic, WAT Medical, Chordate Medical, Chordate Medical, Soterix mEDICAL among others.
Currently, companies such as Athersys, Abbvie, Bristol-Myers Squibb, Lumosa Therapeutics, Teijin Pharma Limited, etc. are involved in developing therapies for Acute Ischemic Stroke (AIS).
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.